The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European ...

The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with ...

And Sanofi solicits new ideas from employees. It even holds an annual Planet Care Challenge offering rewards to workers with ...

--U.S. FDA Delays: Sanofi is potentially exposed to any delays in reviews due to recently announced staff firings at the U.S. Food and Drug Administration. Its anti-inflammatory drug Dupixent was ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) for chronic ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

European pharmaceutical bosses have called on the EU to increase drug prices towards the much higher levels paid by the US, ...

A string of companies, including Sanofi India, Schaeffler India, CIE Automotive, and AMI Organics, will be in focus in the ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...